This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 receptor (RTN4R; NgR) Studies in mice suggest that a soluble peptide fragment of NgR (sNgR)...

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Integrin a9 (ITGA9) Studies in cell culture and in rats suggest that upregulating ITGA9 could help treat...

In an Israeli Phase I trial in 8 patients, ProCord was well tolerated with no evidence of neurological deterioration. Patients were enrolled in the study within 14 days of their injury and had a complete...